StockWatch
·

NACL Industries Ltd

BSE: 524709

P/L Snapshot

Q1 FY27 · standalone

vs Q4 FY26·vs Q1 FY26
Revenue
384.26
+14.6%-12.8%
Expenditure
352.49
+4.8%-16.4%
Net Profit
23.57
+3201.3%+64.8%
OPM %
10.94%
+8.27pp+3.58pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
-100.0552.22204.49356.76509.03Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Price Chart
Reports

NACL Q1: consolidated PAT up 60% to ₹20.8 Cr on margin expansion as revenue slips 14%

agrochemicals · crop protection · margin expansion

ResultsQ1 FY2722 Jul 20263 minMetals & Mining
Latest
Board Meeting22 Jul, 1:55 pm

NACL Q1: consolidated PAT up 60% to ₹20.8 Cr on margin expansion as revenue slips 14%

NACL Industries' Q1 FY27 (quarter ended 30 June 2026) is a bottom-line story: consolidated net profit rose 59.8% year-on-year to ₹20.84 Cr from ₹13.04 Cr, even as revenue from operations fell 14.1% to ₹383.33 Cr (₹448.36 Cr a year ago). The print is clean — no exceptional items this quarter, so the profit jump is not flattered by one-offs; the ₹17.45 Cr consolidated exceptional loss tied to discontinuing certain under-development products belongs to FY26. The profit surge is entirely margin-led: total consolidated expenses fell ~17% YoY (₹431.45 Cr to ₹356.89 Cr), outpacing the 14% revenue decline, lifting net margin to 5.4% from 2.9%. Sequentially the quarter is a turnaround — from a ₹0.86 Cr net loss in Q4 FY26 to a ₹20.84 Cr profit — with revenue up 6.7% QoQ, though for an agrochemical (crop-protection) business the April–June pre-kharif window is seasonally the strongest quarter, so part of the sequential jump is seasonality rather than a fresh demand inflection. A notable wrinkle sits below the profit line: EPS eased to ₹0.60 from ₹0.65 YoY despite the higher absolute profit, because the December 2025 rights issue (32.5M new ₹1 shares) expanded the share count faster than earnings grew — per-share metrics are diluted even as the P&L improved. Standalone profit (₹23.57 Cr, +65% YoY) ran ahead of consolidated, the ~₹2.7 Cr gap reflecting subsidiary losses (one subsidiary posted a ₹3.41 Cr net loss; the associate contributed nil). Both bases tell the same story — revenue down low-double-digits, profit up ~60% on cost-led margin gains — so there is no material standalone/consolidated divergence. Management gives no formal guidance and there is no prior concall or outlook on record, so the print can only be judged on its own merits; no analyst consensus is published for a name this size, so a beat/miss versus street cannot be established. Alongside the results the Board approved divesting the company's entire stake in associate Nasense Labs to Mr. K. Satyanarayana Raju for ₹8.15 Cr (expected to close within three months) and cleared the deviation statement on Rights Issue fund utilisation — ₹24.45 Cr of the rights proceeds remains unutilised, parked in an earmarked bank account. The core question the numbers leave open is whether the topline contraction is demand-driven or a deliberate mix/portfolio shift, and whether the fresh margin level holds.

22 Jul 2026, 01:55 pm

Corporate Events

Board MeetingNACLIND
2026
22Jul

Board Meeting

The 39th Annual General Meeting ('AGM') of the Company along…

BSE Filing ↗
Board MeetingNACLIND
2025
1Dec

Board Meeting

Consideration and approval of fund raising through rights is…

BSE Filing ↗
Board MeetingNACLIND
2025
28May

Board Meeting

Consider and approve Audited Financial Results and take on r…

BSE Filing ↗
Board MeetingNACLIND
2025
14May

Board Meeting

Consider and approve Audited Financial Results and take on r…

BSE Filing ↗
Board MeetingNACLIND
2024
24Oct

Board Meeting

Consideration And Approval Of Unaudited Financial Results

BSE Filing ↗
Board MeetingNACLIND
2024
14Aug

Board Meeting

Consider and approve Unaudited Financial Results

BSE Filing ↗
Board MeetingNACLIND
2024
30May

Board Meeting

Consideration and Approval of Audited Financial Results (bot…

BSE Filing ↗
Board MeetingNACLIND
2024
23May

Board Meeting

Consider and approve Audited Financial Results (Standalone a…

BSE Filing ↗
Board MeetingNACLIND
2024
23Jan

Board Meeting

Consider and approve Unaudited Financial Results (both Stand…

BSE Filing ↗
Board MeetingNACLIND
2023
27Oct

Board Meeting

Consider and approve Unaudited Financial Results (both Stand…

BSE Filing ↗